Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06630091RecruitingPhase 2
Golidocitinib for newly diagnosed peripheral T-cell lymphoma
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
Houston, TexasAges 18 years+ - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT06055361RecruitingPhase 1
Studying a new injection for moderate to severe eczema
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
North Little Rock, ArkansasAges 18 years+ - NCT04627428RecruitingPhase 1/Phase 2
Stem-cell–made eye tissue transplant for dry macular degeneration
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
Beverly Hills, CaliforniaAges 55 years+ - NCT04929236RecruitingPhase 3
Testing different PANZYGA doses for children with CIDP
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Birmingham, AlabamaAges 2–17 - NCT05535361Recruiting
Testing a bowel device for short bowel syndrome patients
This trial studies whether the Eclipse XL1 system is safe and may help people with short bowel syndrome, in both children and adults. It will check how well the approach works and watch for side effects over the study period.
Palo Alto, CaliforniaAges 3 months–65 years - NCT04440436RecruitingPhase 1/Phase 2
IM19 study for relapsed or refractory non-Hodgkin lymphoma
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03755193RecruitingPhase 2
Testing another osteoporosis medicine after 2 years of denosumab
This study looks at how well and how safely another osteoporosis medicine works for people who have already taken denosumab for 2 years. It may help find the best next step to strengthen bones and lower fracture risk after denosumab.
Matsumoto, NaganoAges 20–120 - NCT05588492RecruitingPhase 4
Rifamycin treatment to prevent TB after kidney transplant
This study looks at whether a rifamycin-containing medicine plan is safe and effective at preventing latent (hidden) TB after a kidney transplant. If your TB test shows you likely have hidden TB, you would be offered treatment to reduce the chance it becomes active TB.
TaipeiAges 20 years+ - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07728019RecruitingPhase 2
New drug combo for untreated colon cancer with liver spread
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
Wuhan, HubeiAges 18–75 - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT04920565Recruiting
Hemoperfusion with Polymyxin B for septic shock after heart surgery
This trial studies a blood-filter treatment (hemoperfusion with Polymyxin B) to reduce harmful substances in the blood for people who develop septic shock after heart surgery. It may help by lowering inflammation and improving safety, but it also requires meeting specific signs of severe infection and blood/bleeding conditions.
MoscowAges 18–80 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT07456826Enrolling by invitationPhase 4
Comparing two eye numbing gels for shots
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Tyler, TexasAges 18 years+ - NCT06847555RecruitingPhase 1/Phase 2
Taurine cream to prevent skin burns from radiation in breast cancer
This trial tests if a taurine cream applied to the skin can prevent or reduce the painful skin reactions caused by radiation therapy for breast cancer. It may offer a simple way to protect your skin during treatment.
Jinan, ShandongAges 18 years+ - NCT07361224RecruitingPhase 1
Combining CLS-015 with CAR-T for large B-cell lymphoma
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Tel AvivAges 18 years+ - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,317 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.